View Item 

Show simple item record

A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
dc.contributor.authorEl-Rayes, Bassel F.en_US
dc.contributor.authorZalupski, Mark M.en_US
dc.contributor.authorShields, Anthony F.en_US
dc.contributor.authorFerris, Ann Marieen_US
dc.contributor.authorVaishampayan, Ulkaen_US
dc.contributor.authorHeilbrun, Lance K.en_US
dc.contributor.authorVenkatramanamoorthy, Raghuen_US
dc.contributor.authorAdsay, Volkanen_US
dc.contributor.authorPhilip, Philip A.en_US
dc.date.accessioned2006-09-11T15:52:57Z
dc.date.available2006-09-11T15:52:57Z
dc.date.issued2005-12en_US
dc.identifier.citationEl-Rayes, Basil F.; Zalupski, Mark M.; Shields, Anthony F.; Ferris, Ann Marie; Vaishampayan, Ulka; Heilbrun, Lance K.; Venkatramanamoorthy, Raghu; Adsay, Volkan; Philip, Philip A.; (2005). "A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer." Investigational New Drugs 23(6): 583-590. <http://hdl.handle.net/2027.42/45281>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45281
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16034525&dopt=citationen_US
dc.description.abstractBackground . Pancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was undertaken to determine the effect of gemcitabine by fixed-dose rate infusion (FDR), cisplatin and the COX-2 inhibitor, celecoxib, on the 6-month survival rate in patients with metastatic pancreatic cancer.en_US
dc.format.extent733392 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science + Business Media, Inc.en_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherPancreatic Canceren_US
dc.subject.otherCisplatinen_US
dc.subject.otherCelecoxiben_US
dc.subject.otherGemcitabineen_US
dc.titleA Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic canceren_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, Michigan, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationotherKarmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, United Statesen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid16034525en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45281/1/10637_2005_Article_1028.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s10637-005-1028-zen_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2005_Article_1028.pdf
Size:
716.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.